Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for tissue inhibitor of metalloproteinase- 2
Most Correlated Studies
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Carcinoma of prostate PC3 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
Most Relevant Literature
- Matrix Metalloproteinases (MMP-2) and Tissue Inhibitors of Metalloproteinases (TIMP-2) in Male Ingui…
- Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Func…
- Matrix Metalloproteinases (MMP-2) and Tissue Inhibitors of Metalloproteinases (TIMP-2) in Patients w…
- Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury …
- CSN6 promotes malignant progression of oral squamous cell carcinoma by down-regulating TIMP-2.
Most Relevant Clinical Trials
- Influence of Exercise Program on Serum Matrix Metalloproteinases and Functional Status in Women With…
- Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Chil…
- Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar
- Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic…
- A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With R…
